Yakymyshyna L. Pharmacogenetic approach in the treatment of hypertension candesartan.

The thesis is devoted to optimization of immunosuppressive therapy of hypertension including individual sensitivity to angiotensin receptor blocker candesartan in patients with different genetic variants of polymorphic gene AT 1Р. The leading part of allele C was more severe motion of the disease, early lesions of the target and high risk of cardiovascular complications that must be considered when developing a plan for preventing complications of hypertension. Receptor blockers to angiotensin II candesartan shows sufficient hypotensive effect in all designated genotype AT gene in patients with essential hypertension, with the most pharmacological drug affinity to detect genotypes AС and СС. Candesartan has a positive effect on left ventricular remodeling parameters, especially in patients with genotype CC, which likely reduced end-diastolic dimension and index of left ventricular mass in patients with genotype AС and СС at 12 months compared with index of left ventricular mass relevant indicators to treatment decreased by 5.5% (p <0.05) and 20.2% (p<0.001), respectively.